<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03253094</url>
  </required_header>
  <id_info>
    <org_study_id>SCY-078-204</org_study_id>
    <nct_id>NCT03253094</nct_id>
  </id_info>
  <brief_title>Dose-Finding Study of Oral Ibrexafungep (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis</brief_title>
  <acronym>DOVE</acronym>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Double-Dummy, Active-Controlled, Dose-Finding Study to Compare the Safety and Efficacy of Oral Ibrexafungerp (SCY-078) vs. Oral Fluconazole in Subjects With Acute Vulvovaginal Candidiasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Scynexis, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Scynexis, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a multicenter, randomized, double-blind, double-dummy, active-controlled,&#xD;
      dose-finding study to compare the efficacy, safety and tolerability of oral SCY-078 versus&#xD;
      oral fluconazole in adult female subjects 18 years and older with moderate to severe Acute&#xD;
      Vulvovaginal Candidiasis (AVVC). Approximately 180 eligible subjects (30 subjects per&#xD;
      treatment group) will be enrolled and randomized into the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 2, multicenter, randomized, double-blind, double-dummy, active-controlled,&#xD;
      dose-ranging study of female subjects with moderate to severe Acute Vulvovaginal Candidiasis.&#xD;
      Subjects will be randomized to either the investigational arm (SCY-078) with 5 different dose&#xD;
      regiments ranging from 1 to 3 days of treatment or to the active-control arm (fluconazole)&#xD;
      for 1 day of treatment. After randomization subjects may be seen on study Day 3 (on site&#xD;
      visit for PK subjects) , Day 10 (±2,) and Day 25 (+4).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 1, 2017</start_date>
  <completion_date type="Actual">May 4, 2018</completion_date>
  <primary_completion_date type="Actual">May 4, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>randomized, double-blind, double-dummy, active-controlled, dose-finding</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical Cure (Complete Resolution of Signs and Symptoms)</measure>
    <time_frame>8-12 days</time_frame>
    <description>Measured by the percentage of subjects with clinical cure (complete resolution of signs and symptoms) at the test-of-cure (TOC) visit</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Co-occurrence of Clinical and Mycological Cure</measure>
    <time_frame>29 days</time_frame>
    <description>The percentage of subjects with both clinical cure and mycological eradication (negative fungal culture) the Test-of cure.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Treatment Emergent Adverse Events</measure>
    <time_frame>up to 29 days</time_frame>
    <description>The number of subjects with treatment related adverse events</description>
  </other_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">186</enrollment>
  <condition>Candida Vulvovaginitis</condition>
  <arm_group>
    <arm_group_label>Fluconazole</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>150 mg/day for 1 day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibrexafungerp 750mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>750mg QD for 1 day only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibrexafungerp 300mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg BID for 1 day only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibrexafungerp 450mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>450mg BID for 1 day only</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibrexafungerp 150mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150mg BID for 3 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ibrexafungerp 300mg D1-D3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>300mg BID for 3 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole</intervention_name>
    <description>Oral Antifungal comparator</description>
    <arm_group_label>Fluconazole</arm_group_label>
    <other_name>Diflucan, Azole antifungal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SCY-078</intervention_name>
    <description>Investigational Antifungal</description>
    <arm_group_label>Ibrexafungerp 150mg</arm_group_label>
    <arm_group_label>Ibrexafungerp 300mg</arm_group_label>
    <arm_group_label>Ibrexafungerp 300mg D1-D3</arm_group_label>
    <arm_group_label>Ibrexafungerp 450mg</arm_group_label>
    <arm_group_label>Ibrexafungerp 750mg</arm_group_label>
    <other_name>Ibrexafungerp</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Subject is a female of at least 18 years of age&#xD;
&#xD;
          2. Subject has a diagnosis of symptomatic AVVC at baseline including a positive&#xD;
             microscopic examination with 10% KOH in a vaginal sample revealing yeast forms&#xD;
             (hyphae/pseudohyphae) or budding yeasts, and vaginal pH (≤4.5)&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. Subject has any vaginal condition other than AVVC that may interfere with the&#xD;
             diagnosis or evaluation of response to therapy, such as suspected or confirmed&#xD;
             concurrent causes of vulvovaginitis and/or cervicitis (mixed infection)&#xD;
&#xD;
          2. Need for systemic and/or topical (vaginal) antifungal treatment, including&#xD;
             prescription or over-the-counter products during the study and treatment for VVC 28&#xD;
             days prior to randomization&#xD;
&#xD;
          3. Subject is actively menstruating at the time of the Baseline visit.&#xD;
&#xD;
          4. Subject has uncontrolled diabetes mellitus.&#xD;
&#xD;
          5. Subject has a vaginal sample with pH &gt;4.5.&#xD;
&#xD;
          6. Subject has a history of or an active cervical/vaginal cancer.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Angulo, MD</last_name>
    <role>Study Director</role>
    <affiliation>Scynexis, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UAB Personal Health Clinic</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Trials AZ, LLC</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Care Research Corp.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gulf Coast Research Group, LLC</name>
      <address>
        <city>Brandon</city>
        <state>Florida</state>
        <zip>33510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Altus Research, Inc.</name>
      <address>
        <city>Lake Worth</city>
        <state>Florida</state>
        <zip>33461</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>OB-GYN Associates of Mid-Florida P.A.</name>
      <address>
        <city>Leesburg</city>
        <state>Florida</state>
        <zip>34748</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Age Medical Research Corp.</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visionary Investigators Network</name>
      <address>
        <city>South Miami</city>
        <state>Florida</state>
        <zip>33160</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atlanta North Gynecology, P.C.</name>
      <address>
        <city>Roswell</city>
        <state>Georgia</state>
        <zip>30075</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cypress Medical Research Center, LLC</name>
      <address>
        <city>Wichita</city>
        <state>Kansas</state>
        <zip>67226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management, LLC</name>
      <address>
        <city>Covington</city>
        <state>Louisiana</state>
        <zip>70433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials Management, LLC</name>
      <address>
        <city>Metairie</city>
        <state>Louisiana</state>
        <zip>70006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women Under Study, LLC</name>
      <address>
        <city>New Orleans</city>
        <state>Louisiana</state>
        <zip>70125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tolan Park Medical Building</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Consultants in Women's Healthcare, Inc.</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrence OB/GYN Clinical Research, LLC</name>
      <address>
        <city>Lawrenceville</city>
        <state>New Jersey</state>
        <zip>08648</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Women's Health Research Center</name>
      <address>
        <city>Plainsboro</city>
        <state>New Jersey</state>
        <zip>08536</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Unified Women's Clinical Research - Central Carolina</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wake Research Associates, LLC</name>
      <address>
        <city>Raleigh</city>
        <state>North Carolina</state>
        <zip>27612</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Research South, LLC</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>WR-Medical Research Center of Memphis, LLC</name>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <zip>38120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tmc Life Research, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Trials of Texas, Inc.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seattle Women's Health, Research, Gynecology</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98105</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 14, 2017</study_first_submitted>
  <study_first_submitted_qc>August 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 17, 2017</study_first_posted>
  <results_first_submitted>June 30, 2021</results_first_submitted>
  <results_first_submitted_qc>August 11, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">August 12, 2021</results_first_posted>
  <disposition_first_submitted>October 20, 2020</disposition_first_submitted>
  <disposition_first_submitted_qc>August 11, 2021</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">August 12, 2021</disposition_first_posted>
  <last_update_submitted>August 11, 2021</last_update_submitted>
  <last_update_submitted_qc>August 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Candidiasis, Vulvovaginal</mesh_term>
    <mesh_term>Vulvovaginitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
    <mesh_term>Ibrexafungerp</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 13, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03253094/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 6, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03253094/SAP_002.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ibrexafungerp 750-mg</title>
          <description>750 mg QD for 1 day only</description>
        </group>
        <group group_id="P2">
          <title>Ibrexafungerp 300-mg</title>
          <description>300 mg BID for 1 day only</description>
        </group>
        <group group_id="P3">
          <title>Ibrexafungerp 450-mg</title>
          <description>450 mg BID for 1 day only</description>
        </group>
        <group group_id="P4">
          <title>Ibrexafungerp 150-mg</title>
          <description>150 mg BID for 3 days</description>
        </group>
        <group group_id="P5">
          <title>Ibrexafungerp 300-mg (3 Days)</title>
          <description>300 mg BID for 3 days</description>
        </group>
        <group group_id="P6">
          <title>Fluconazole</title>
          <description>150 mg QD for 1 day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="32"/>
                <participants group_id="P2" count="30"/>
                <participants group_id="P3" count="28"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="32"/>
                <participants group_id="P6" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Subjects Discontinued</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="28"/>
                <participants group_id="P2" count="27"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="28"/>
                <participants group_id="P5" count="27"/>
                <participants group_id="P6" count="28"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="6"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="5"/>
                <participants group_id="P6" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ibrexafungerp 750-mg</title>
          <description>750 mg QD for 1 day only</description>
        </group>
        <group group_id="B2">
          <title>Ibrexafungerp 300-mg</title>
          <description>300 mg BID for 1 day only</description>
        </group>
        <group group_id="B3">
          <title>Ibrexafungerp 450-mg</title>
          <description>450 mg BID for 1 day only</description>
        </group>
        <group group_id="B4">
          <title>Ibrexafungerp 150-mg</title>
          <description>150 mg BID for 3 days</description>
        </group>
        <group group_id="B5">
          <title>Ibrexafungerp 300-mg (3 Days)</title>
          <description>300 mg BID for 3 days</description>
        </group>
        <group group_id="B6">
          <title>Fluconazole</title>
          <description>150 mg QD for 1 day</description>
        </group>
        <group group_id="B7">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="32"/>
            <count group_id="B2" value="30"/>
            <count group_id="B3" value="28"/>
            <count group_id="B4" value="32"/>
            <count group_id="B5" value="32"/>
            <count group_id="B6" value="32"/>
            <count group_id="B7" value="186"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34.6" spread="12.3"/>
                    <measurement group_id="B2" value="34.4" spread="11.3"/>
                    <measurement group_id="B3" value="34.5" spread="9.8"/>
                    <measurement group_id="B4" value="33.3" spread="10.5"/>
                    <measurement group_id="B5" value="32.0" spread="8.5"/>
                    <measurement group_id="B6" value="33.8" spread="10.1"/>
                    <measurement group_id="B7" value="33.7" spread="10.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="186"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="11"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="11"/>
                    <measurement group_id="B7" value="56"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="21"/>
                    <measurement group_id="B5" value="25"/>
                    <measurement group_id="B6" value="21"/>
                    <measurement group_id="B7" value="130"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="12"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="15"/>
                    <measurement group_id="B6" value="13"/>
                    <measurement group_id="B7" value="72"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="14"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="16"/>
                    <measurement group_id="B6" value="19"/>
                    <measurement group_id="B7" value="109"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                    <measurement group_id="B7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="30"/>
                    <measurement group_id="B3" value="28"/>
                    <measurement group_id="B4" value="32"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="32"/>
                    <measurement group_id="B7" value="186"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Clinical Cure (Complete Resolution of Signs and Symptoms)</title>
        <description>Measured by the percentage of subjects with clinical cure (complete resolution of signs and symptoms) at the test-of-cure (TOC) visit</description>
        <time_frame>8-12 days</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrexafungerp 750-mg</title>
            <description>750 mg QD D1 only</description>
          </group>
          <group group_id="O2">
            <title>Ibrexafungerp 300-mg</title>
            <description>300 mg BID D1 only</description>
          </group>
          <group group_id="O3">
            <title>Ibrexafungerp 450-mg</title>
            <description>450 mg BID D1 only</description>
          </group>
          <group group_id="O4">
            <title>Ibrexafungerp 150-mg</title>
            <description>150 mg BID D1 to D3</description>
          </group>
          <group group_id="O5">
            <title>Ibrexafungerp 300-mg D1 to D3</title>
            <description>300 mg BID D1 to D3</description>
          </group>
          <group group_id="O6">
            <title>Fluconazole</title>
            <description>150 mg QD D1 only</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Cure (Complete Resolution of Signs and Symptoms)</title>
          <description>Measured by the percentage of subjects with clinical cure (complete resolution of signs and symptoms) at the test-of-cure (TOC) visit</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Clinical cure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="9"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="13"/>
                    <measurement group_id="O4" value="14"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clinical failure</title>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="8"/>
                    <measurement group_id="O4" value="15"/>
                    <measurement group_id="O5" value="11"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Co-occurrence of Clinical and Mycological Cure</title>
        <description>The percentage of subjects with both clinical cure and mycological eradication (negative fungal culture) the Test-of cure.</description>
        <time_frame>29 days</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>Ibrexafungerp 750-mg</title>
            <description>750 mg QD D1 only</description>
          </group>
          <group group_id="O2">
            <title>Ibrexafungerp 300-mg</title>
            <description>300 mg BID D1 only</description>
          </group>
          <group group_id="O3">
            <title>Ibrexafungerp 450-mg</title>
            <description>450 mg BID D1 only</description>
          </group>
          <group group_id="O4">
            <title>Ibrexafungerp 150-mg</title>
            <description>150 mg BID D1 to D3</description>
          </group>
          <group group_id="O5">
            <title>Ibrexafungerp 300-mg D1 to D3</title>
            <description>300 mg BID D1 to D3</description>
          </group>
          <group group_id="O6">
            <title>Fluconazole</title>
            <description>150 mg QD D1 only</description>
          </group>
        </group_list>
        <measure>
          <title>Co-occurrence of Clinical and Mycological Cure</title>
          <description>The percentage of subjects with both clinical cure and mycological eradication (negative fungal culture) the Test-of cure.</description>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="26"/>
                <count group_id="O2" value="27"/>
                <count group_id="O3" value="21"/>
                <count group_id="O4" value="29"/>
                <count group_id="O5" value="26"/>
                <count group_id="O6" value="24"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Clinical cure and Mycological Eradication</title>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="10"/>
                    <measurement group_id="O3" value="11"/>
                    <measurement group_id="O4" value="8"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Clinical failure and/or mycological persistence</title>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="17"/>
                    <measurement group_id="O3" value="10"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="13"/>
                    <measurement group_id="O6" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Treatment Emergent Adverse Events</title>
        <description>The number of subjects with treatment related adverse events</description>
        <time_frame>up to 29 days</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ibrexafungerp 750-mg</title>
            <description>750 mg QD D1 only</description>
          </group>
          <group group_id="O2">
            <title>Ibrexafungerp 300-mg</title>
            <description>300 mg BID D1 only</description>
          </group>
          <group group_id="O3">
            <title>Ibrexafungerp 450-mg</title>
            <description>450 mg BID D1 only</description>
          </group>
          <group group_id="O4">
            <title>Ibrexafungerp 150-mg</title>
            <description>150 mg BID D1 to D3</description>
          </group>
          <group group_id="O5">
            <title>Ibrexafungerp 300-mg D1 to D3</title>
            <description>300 mg BID D1 to D3</description>
          </group>
          <group group_id="O6">
            <title>Fluconazole</title>
            <description>150 mg QD D1 only</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Treatment Emergent Adverse Events</title>
          <description>The number of subjects with treatment related adverse events</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="32"/>
                <count group_id="O2" value="30"/>
                <count group_id="O3" value="28"/>
                <count group_id="O4" value="31"/>
                <count group_id="O5" value="32"/>
                <count group_id="O6" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Treatment related Treatment-emergent adverse event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="20"/>
                    <measurement group_id="O2" value="14"/>
                    <measurement group_id="O3" value="16"/>
                    <measurement group_id="O4" value="12"/>
                    <measurement group_id="O5" value="15"/>
                    <measurement group_id="O6" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>No Treatment related Treatment-emergent adverse event</title>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="16"/>
                    <measurement group_id="O3" value="12"/>
                    <measurement group_id="O4" value="19"/>
                    <measurement group_id="O5" value="17"/>
                    <measurement group_id="O6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>29 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ibrexafungerp 750-mg</title>
          <description>750 mg QD D1 only</description>
        </group>
        <group group_id="E2">
          <title>Ibrexafungerp 300-mg</title>
          <description>300 mg BID D1 only</description>
        </group>
        <group group_id="E3">
          <title>Ibrexafungerp 450-mg</title>
          <description>450 mg BID D1 only</description>
        </group>
        <group group_id="E4">
          <title>Ibrexafungerp 150-mg</title>
          <description>150 mg BID D1 to D3</description>
        </group>
        <group group_id="E5">
          <title>Ibrexafungerp 300-mg D1 to D3</title>
          <description>300 mg BID D1 to D3</description>
        </group>
        <group group_id="E6">
          <title>Fluconazole</title>
          <description>150 mg QD D1 only</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="18" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="10" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="3" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="9" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="32"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="30"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="28"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="1" subjects_at_risk="32"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. David Angulo</name_or_title>
      <organization>SCYNEXIS</organization>
      <phone>(201) 884 - 5471</phone>
      <email>david.angulo@scynexis.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

